<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Asbestos-related pleuropulmonary disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Asbestos-related pleuropulmonary disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Asbestos-related pleuropulmonary disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Asbestos is the general term for a group of naturally occurring fibers composed of hydrated magnesium silicates. The spectrum of pleuropulmonary disorders associated with asbestos exposure includes [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Asbestosis</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural disease (benign asbestos effusion, focal and diffuse benign pleural plaques)</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies (non-small cell and small cell carcinoma of the lung as well as malignant mesothelioma)</p><p></p><p>Asbestosis specifically refers to the pneumoconiosis caused by inhalation of asbestos fibers. The disease is characterized by slowly progressive, diffuse pulmonary fibrosis. Asbestosis remains a significant clinical problem despite substantial reductions in occupational asbestos exposure, due to occupational exposure that occurred years earlier [<a href="#rid3">3,4</a>]. </p><p>The pathophysiologic mechanisms and clinical manifestations of asbestos-related pleuropulmonary disease will be reviewed here [<a href="#rid1">1,5-7</a>]. The approach to the patient with suspected interstitial lung disease is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ASBESTOS EXPOSURE</span><span class="headingEndMark"> — </span>Asbestos is the general term for a group of naturally occurring fibers composed of hydrated magnesium silicates used for a variety of construction and insulating purposes.</p><p>Asbestos fibers are divided into two categories based on their shape. <strong>Serpentine</strong> fibers, of which chrysotile is the main commercial variety, are long, curly strands, whereas <strong>amphibole</strong> fibers (crocidolite, amosite, tremolite, and others) are long, straight, rod-like structures. Chrysotile accounts for over 90 percent of the asbestos in commercial use in the United States and is generally considered less toxic than the amphibole fibers [<a href="#rid5">5,8,9</a>].</p><p>When the use of asbestos was widespread, exposure occurred in a variety of occupational and non-occupational settings  (<a class="graphic graphic_table graphicRef67902" href="/z/d/graphic/67902.html" rel="external">table 1</a>). As examples, exposure to asbestos resulted from involvement with the following [<a href="#rid7">7,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mining and milling of the fibers</p><p class="bulletIndent1"><span class="glyph">●</span>Industrial and occupational applications of asbestos (eg, work with textiles, cement, friction materials, insulation, shipbuilding)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonoccupational exposure to airborne asbestos (eg, regular exposure to soiled work clothes brought home by an asbestos worker, renovation or demolition of asbestos-containing buildings, environmental exposure in the neighborhood of industrial sources, and natural environmental exposure to geological sources)</p><p></p><p>Commercial use of asbestos is banned in many countries. In the United States, asbestos use has been limited since the 1970s, but is still permitted in automotive brake pads and gaskets, roofing products, and fireproof clothing. Mining of asbestos is ongoing in several countries, most prominently Russia, China, Brazil, and Kazakhstan [<a href="#rid11">11</a>]. </p><p>Environmental exposure to low levels of asbestos from naturally occurring sources or industrial emissions may increase the risk of malignant mesothelioma, but not asbestosis [<a href="#rid12">12-15</a>]. The health risk to occupants of a building in which asbestos is in good repair and undisturbed (ie, not respirable) is <strong>not</strong> considered significant [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2283837394"><span class="h1">ASBESTOSIS</span><span class="headingEndMark"> — </span>Asbestosis specifically refers to the slowly progressive, diffuse pulmonary fibrosis caused by inhalation of asbestos fibers.</p><p class="headingAnchor" id="H3246595298"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>The gross anatomic features of asbestosis include the presence of small, stiff lungs with fibrosis in the subpleural regions of the lower lobes. The adjacent visceral pleura may also be fibrotic and associated with parietal pleural plaques, while the central portions of the lung are relatively spared  (<a class="graphic graphic_picture graphicRef66468" href="/z/d/graphic/66468.html" rel="external">picture 1</a>) [<a href="#rid16">16</a>].</p><p>The histopathologic diagnosis of asbestosis requires the presence of uncoated or coated asbestos fibers (asbestos bodies) in association with interstitial pulmonary fibrosis that is similar in appearance to usual interstitial pneumonitis (UIP)  (<a class="graphic graphic_picture graphicRef61838 graphicRef81274 graphicRef70440 graphicRef59362 graphicRef50185" href="/z/d/graphic/61838.html" rel="external">picture 2A-E</a> and <a class="graphic graphic_picture graphicRef73648" href="/z/d/graphic/73648.html" rel="external">picture 3</a>) [<a href="#rid17">17,18</a>]. Pulmonary fibrosis in asbestosis differs from that of UIP in two important ways [<a href="#rid18">18</a>]. Fibroblast foci, which are characteristic of UIP, are infrequent in asbestosis. In addition, asbestosis is typically associated with mild fibrosis of the visceral pleura. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Pathology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asbestos bodies</strong> — Asbestos bodies are composed of transparent asbestos fibers surrounded by a coating of iron and protein. Such a coating may surround a number of other mineral particles, such as glass, talc, iron, or carbon; the resulting structures are generically called ferruginous bodies. Asbestos bodies are differentiated from other ferruginous bodies by their transparent core [<a href="#rid18">18</a>]. Light microscopy does not allow accurate determination of the mineral at the core of a ferruginous body, and definitive identification may require scanning electron microscopy with energy dispersive x-ray analysis of lung specimens. Amphibole fibers form asbestos bodies more readily than do chrysotile fibers, in part due to the less efficient pulmonary clearance of amphiboles [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1">Two or more asbestos bodies per square centimeter of a 5-mu thick lung section, in combination with interstitial fibrosis, are indicative of asbestosis [<a href="#rid18">18</a>]. The quantity of asbestos fibers in the lungs (both coated and uncoated) is generally 10 to 20-fold higher in patients with asbestosis compared with unexposed individuals and correlates with the severity of fibrosis [<a href="#rid19">19</a>]. Quantification of asbestos bodies by light microscopy significantly underestimates the total lung fiber burden. The number of asbestos bodies in digested lung is generally 10 to 10,000-fold less than the total number of uncoated fibers determined by electron microscopy [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Asbestos-induced diseases are probably caused by the direct toxic effects of the fibers on pulmonary parenchymal cells as well as the release of various mediators (reactive oxygen species, proteases, cytokines, and growth factors) by inflammatory cells [<a href="#rid20">20-22</a>]. Deleterious reactive oxygen and nitrogen free radicals may be formed either via reactions catalyzed by iron molecules within asbestos bodies or as a consequence of the activation of inflammatory cells. Free radicals can react with and damage a variety of cellular macromolecules and may disrupt DNA to give rise to malignancy [<a href="#rid16">16</a>].</p><p>Animal models suggest that inhaled asbestos fibers deposit at respiratory bronchiole and alveolar duct bifurcations [<a href="#rid23">23-25</a>]. This triggers the accumulation of alveolar macrophages and the development of an inflammatory reaction that extends centrifugally into the terminal respiratory bronchioles and adjacent alveolar interstitium [<a href="#rid23">23-25</a>]. The majority of fibers are removed from the lungs by mucociliary mechanisms, but some are taken up by alveolar macrophages and alveolar type I cells [<a href="#rid23">23</a>]. </p><p>Amphibole fibers may be more toxic than chrysotile because their structure allows them to deposit more efficiently in the distal lung parenchyma and reduces their rate of clearance [<a href="#rid22">22</a>]. Smoking increases the attack and/or progression rate of asbestosis, probably by interfering with the mucociliary clearance of inhaled fibers [<a href="#rid26">26,27</a>]. </p><p>Over time, there is more diffuse pulmonary involvement characterized by loss of alveolar type I and II cells and expansion of the numbers of alveolar and interstitial macrophages, neutrophils, lymphocytes, and eosinophils. Fibroblast proliferation and collagen accumulation ultimately result [<a href="#rid25">25,28,29</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Clinical findings</span><span class="headingEndMark"> — </span>Most patients who develop asbestosis are asymptomatic for at least 20 to 30 years after the initial exposure; the latency period between exposure and symptoms is inversely proportional to the intensity of asbestos exposure [<a href="#rid5">5,6,16,30</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – The earliest symptom of asbestosis is usually the insidious onset of breathlessness with exertion. Dyspnea commonly progresses even in the absence of further asbestos exposure. Cough, sputum production, and wheezing are unusual; if present, these symptoms tend to be a consequence of cigarette smoking rather than asbestos-induced lung disease [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – As asbestosis progresses, patients may develop bibasilar, fine end-inspiratory crackles (32 to 64 percent) and clubbing (32 to 42 percent) [<a href="#rid31">31,32</a>]. Cor pulmonale may ensue in advanced cases and may cause peripheral edema, jugular venous distension, hepatojugular reflux, and/or a right ventricular heave or gallop. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong> – Laboratory studies are generally nonspecific and not useful clinically. Antinuclear antibodies, rheumatoid factor, and an elevated erythrocyte sedimentation rate may be present but do not correlate with disease severity or activity [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H1654172238"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The evaluation of suspected asbestosis in a patient with a history of asbestos exposure generally includes pulmonary function testing to assess the severity and pattern of lung impairment and imaging to look for characteristic features of asbestosis. Bronchoalveolar lavage (BAL) has a limited role.</p><p class="headingAnchor" id="H8"><span class="h3">Pulmonary function tests</span><span class="headingEndMark"> — </span>In the evaluation of dyspnea in a patient with possible asbestosis, pulmonary function testing should include spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO). (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>The characteristic lung function abnormalities in patients with asbestosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced lung volumes, particularly the vital capacity and total lung capacity</p><p class="bulletIndent1"><span class="glyph">●</span>Diminished DLCO</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased pulmonary compliance</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of airflow obstruction by spirometry (normal ratio of the forced expiratory volume in one second to forced vital capacity)</p><p></p><p>The earliest physiologic abnormalities detected in asbestos-exposed patients are reductions in the DLCO and pulmonary compliance and the presence of exertional hypoxemia [<a href="#rid31">31,34</a>]. Although hypoxemia early in the course of disease occurs only with exercise, more advanced disease can be associated with hypoxemia at rest.</p><p>Airways obstruction generally reflects concomitant exposure to cigarette smoke, but rarely occurs in the absence of tobacco exposure [<a href="#rid35">35</a>]. Airflow limitation in these patients may be due to airway inflammation resulting from asbestos deposition along the respiratory bronchioles and alveolar duct bifurcations  (<a class="graphic graphic_picture graphicRef58775" href="/z/d/graphic/58775.html" rel="external">picture 4</a>).</p><p class="headingAnchor" id="H9"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>Imaging studies are an integral part of the evaluation of adult-onset dyspnea and of suspected asbestosis. (See  <a class="medical medical_review" href="/z/d/html/14874.html" rel="external">"Imaging of occupational lung diseases", section on 'Asbestos-related thoracic diseases'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> – The chest radiograph in patients with asbestosis usually reveals small bilateral parenchymal opacities with a multinodular or reticular pattern, often with associated pleural abnormalities [<a href="#rid36">36,37</a>]. These findings may be subtle. In one study, for example, 15 to 20 percent of individuals with histopathologic evidence of pulmonary fibrosis had no interstitial abnormalities on their chest radiographs [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1">The interstitial process typically begins in the lower lung zones and is associated with bilateral mid-lung zone plaques on the parietal pleura. In the early stages of asbestosis, combined interstitial and pleural involvement may cause a hazy, "ground glass" appearance to the chest radiograph that may blur the diaphragm and heart border, giving rise to the "shaggy heart" sign  (<a class="graphic graphic_diagnosticimage graphicRef81236" href="/z/d/graphic/81236.html" rel="external">image 1</a>) [<a href="#rid36">36</a>]. Honeycombing and upper lobe involvement develop in advanced stages of disease  (<a class="graphic graphic_diagnosticimage graphicRef56976" href="/z/d/graphic/56976.html" rel="external">image 2</a>). Hilar and mediastinal lymphadenopathy are not seen with asbestosis and should suggest the presence of another process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High resolution computed tomography</strong> — High resolution computed tomography (HRCT) is more sensitive than plain films in detecting parenchymal abnormalities in asbestos-exposed individuals [<a href="#rid39">39-43</a>]. Up to 30 percent of asbestos-exposed individuals demonstrate an abnormal HRCT in spite of a normal chest radiograph [<a href="#rid44">44</a>]. However, HRCT may still appear normal or near normal in cases of histopathologically proven asbestosis [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">The characteristic HRCT findings of asbestosis include  (<a class="graphic graphic_diagnosticimage graphicRef91540" href="/z/d/graphic/91540.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef91628" href="/z/d/graphic/91628.html" rel="external">image 4</a>) [<a href="#rid41">41,42,44-47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subpleural linear densities of varying length parallel to the pleura</p><p class="bulletIndent2"><span class="glyph">•</span>Basilar and dorsal lung parenchymal fibrosis, with peribronchiolar, intralobular, and interlobular septal fibrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Coarse parenchymal bands (2 to 5 cm in length), often contiguous with the pleura</p><p class="bulletIndent2"><span class="glyph">•</span>Coarse honeycombing in advanced disease</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural plaques, which help differentiate asbestos-induced parenchymal disease from other interstitial lung diseases (see <a class="local">'Pleural plaques and diffuse pleural thickening'</a> below)</p><p></p><p class="bulletIndent1">The significance of abnormal HRCT scans in asymptomatic asbestos-exposed persons as well as the proper role of HRCT in detection of asbestos-induced lung disease need further study.</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Bronchoalveolar lavage</span><span class="headingEndMark"> — </span>While quantification of asbestos bodies in BAL fluid roughly correlates with the burden of lung parenchymal asbestos bodies, the clinical utility of BAL for evaluation of possible asbestosis is limited. We reserve BAL for patients in whom the HRCT is not sufficiently diagnostic, and malignancy, infection, or hypersensitivity pneumonitis are in the differential diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a>.)</p><p>Studies have shown that increased numbers of asbestos bodies are found in sputum and BAL fluid of asbestos workers with asbestosis compared with asbestos workers with a normal chest radiograph and also in those with more intense asbestos exposure [<a href="#rid48">48,49</a>]. Greater than one asbestos body/mL of BAL fluid correlates with more than 1000 asbestos bodies/gram of lung tissue in patients with suspected asbestos-related disease [<a href="#rid50">50</a>]; such levels are associated with significant exposure. However, interpretation of the results is difficult because of marked interpatient variation and the fact that a significant number of asbestos fibers may be present in exposed individuals without disease [<a href="#rid19">19,51</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>For the majority of patients, a confident clinical diagnosis of asbestosis can be made on the basis of the exposure history and the HRCT findings (see <a class="local">'Imaging'</a> above). Examination of lung tissue is rarely needed to establish a diagnosis  (<a class="graphic graphic_table graphicRef56557" href="/z/d/graphic/56557.html" rel="external">table 2</a>) [<a href="#rid17">17,28,34,52</a>]. There are three key findings that support the diagnosis of asbestosis  (<a class="graphic graphic_table graphicRef61308 graphicRef71021" href="/z/d/graphic/61308.html" rel="external">table 3A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A reliable history of exposure to asbestos with a proper latency period from the onset of exposure to the time of presentation, and/or presence of markers of exposure (eg, pleural plaques, which are virtually pathognomonic of previous exposure, or recovery of sufficient quantities of asbestos fibers/bodies in bronchoalveolar lavage or lung tissue) [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Definite evidence of interstitial fibrosis, as manifested by one or more of the following: end-inspiratory crackles on chest examination; reduced lung volumes and/or DLCO; presence of typical chest radiograph or HRCT findings of interstitial lung disease; or histologic evidence of interstitial fibrosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of other causes of diffuse parenchymal lung disease. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Causes of ILD'</a>.)</p><p></p><p class="headingAnchor" id="H772826529"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of asbestosis includes idiopathic pulmonary fibrosis and diseases that are associated with usual interstitial pneumonia or fibrotic nonspecific interstitial pneumonia, such as rheumatoid arthritis and other rheumatic diseases, chronic hypersensitivity pneumonitis, drug-induced pneumonitis, combined pulmonary fibrosis and emphysema, and pleuropulmonary fibroelastosis, although chronic hypersensitivity pneumonitis and pleuropulmonary fibroelastosis tend to be upper lobe predominant. The characteristics of these diseases are described separately. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">"Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Management</span><span class="headingEndMark"> — </span>There is currently <strong>no</strong> specific treatment for asbestosis. There have been no prospective studies of patients with asbestosis utilizing antiinflammatory or immunosuppressive agents, such as glucocorticoids or cytotoxic therapy, or antifibrotic agents [<a href="#rid54">54</a>]. The absence of inflammation on histopathologic examination makes it unlikely that anti-inflammatory or immunosuppressive agents would be of benefit.</p><p>Thus, management of patients with asbestosis should focus on preventive and supportive measures, including  (<a class="graphic graphic_table graphicRef78800" href="/z/d/graphic/78800.html" rel="external">table 4</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking cessation</p><p class="bulletIndent1"><span class="glyph">●</span>Early detection of physiologic and radiographic abnormalities to aid prevention of further airborne asbestos exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Supplemental oxygen when there is resting hypoxemia or exercise-induced oxygen desaturation</p><p class="bulletIndent1"><span class="glyph">●</span>Prompt treatment of respiratory infections</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal and influenza vaccination  (<a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">table 5</a>)</p><p></p><p>Whole lung lavage has been investigated as a means for removing retained dust in some pneumoconioses, but has not been applied to patients with asbestosis [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Complications</span><span class="headingEndMark"> — </span>The two main complications of asbestosis are respiratory failure and malignancy.</p><p class="headingAnchor" id="H20"><span class="h3">Respiratory failure</span><span class="headingEndMark"> — </span>Asbestosis is a slowly progressive process that culminates in respiratory failure in a minority of patients. Risk factors for progression of lung function abnormalities in asbestos-exposed individuals include [<a href="#rid30">30,56,57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cumulative asbestos exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Fiber type (crocidolite exposure is associated with the most frequent progression)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse pleural thickening (see <a class="local">'Pleural plaques and diffuse pleural thickening'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Honeycombing on HRCT (see <a class="local">'Imaging'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Radiographic pattern consistent with typical or probable UIP  (<a class="graphic graphic_table graphicRef107408" href="/z/d/graphic/107408.html" rel="external">table 6</a>) other than the presence of pleural plaques</p><p></p><p>Baseline PFTs and risk-predicting models, such as the gender, age and physiologic (GAP) variables model [<a href="#rid58">58</a>] and composite physiologic index (CPI), can help predict survival [<a href="#rid59">59,60</a>].</p><p>Cigarette smoke may accelerate the progression of pulmonary fibrosis after asbestos exposure [<a href="#rid61">61</a>]. Although the mechanisms for this synergistic interaction are unknown, reactive oxygen species have been implicated as having a prominent role [<a href="#rid5">5,6,62</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Malignancy</span><span class="headingEndMark"> — </span>Although some investigators have questioned the causal relationship between asbestosis and bronchogenic carcinoma, most studies have demonstrated a clear association between the two entities [<a href="#rid43">43,63-65</a>]. As an example, a Dutch cohort study of 58,279 men, in which 524 cases of lung cancer developed, found that asbestos exposure was associated with a relative risk of lung cancer of 3.5 (95 percent CI 1.7 to 7.2) after adjustment for age, smoking habits, and intake of vitamin C, <a class="drug drug_general" data-topicid="9127" href="/z/d/drug information/9127.html" rel="external">beta-carotene</a>, and retinol [<a href="#rid66">66</a>]. A systematic review and meta-analysis found an increased risk of lung cancer associated with environmental exposure to asbestos, especially in neighborhoods near asbestos mines and factories [<a href="#rid67">67</a>].</p><p>The risk of lung cancer associated with asbestos is greatly magnified by coexisting exposure to tobacco smoke. A meta-analysis examined the risk of lung cancer in asbestos exposed smokers and nonsmokers: Compared with nonsmokers without asbestos exposure, the odds ratios for developing lung cancer were 1.70 (95% CI 1.31–2.21) among asbestos-exposed nonsmokers, 5.65 (95% CI 3.38–9.42) among smokers without asbestos exposure, and 8.70 (95% CI 5.8–13.10) among asbestos-exposed smokers [<a href="#rid68">68</a>].</p><p>In an earlier series of asbestos workers, the risk of dying of lung cancer increased 16-fold if they smoked more than 20 cigarettes per day and 9-fold if they smoked fewer than 20 cigarettes per day, compared with asbestos workers without a regular smoking history [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.)</p><p>For any given individual, the relative risk depends upon the magnitude of the exposure both to cigarette smoke and to asbestos. The type of asbestos fiber affects the risk of lung cancer as well; the risk appears to be considerably higher for workers exposed to amphibole fibers than for those exposed to chrysotile fibers [<a href="#rid8">8,70</a>]. However, an analysis of 35-year prospective cohort data suggested a significant exposure-response relationship between exposure to chrysotile asbestos and increased risk for lung cancer mortality [<a href="#rid71">71</a>]. </p><p>Asbestos exposure increases the incidence of other neoplasms as well [<a href="#rid5">5,6,72</a>]. Other malignancies that have been linked to asbestos include cancers of the larynx, oropharynx, kidney, esophagus, and biliary system [<a href="#rid72">72</a>]. Asbestos is the <strong>only</strong> known risk factor for malignant mesothelioma. (See <a class="local">'Malignant mesothelioma'</a> below and  <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H2618324722"><span class="h1">PLEURAL DISEASE</span><span class="headingEndMark"> — </span>Pleural involvement is a hallmark of asbestos exposure but is unusual in other interstitial lung disorders. </p><p class="headingAnchor" id="H2476637934"><span class="h2">Benign asbestos pleural effusion</span><span class="headingEndMark"> — </span>Benign asbestos pleural effusions (BAPEs) are usually small and unilateral and occur years before the onset of interstitial disease [<a href="#rid7">7,73,74</a>]. The duration of asbestos exposure prior to BAPE is variably reported as a mean of 5.5 years [<a href="#rid75">75</a>] to a mean of 28 years [<a href="#rid76">76</a>], while the interval between exposure and onset of BAPE is reported as 15 years [<a href="#rid75">75</a>] to 46 years [<a href="#rid76">76</a>]. The correlation between the exposure amount and development of BAPE is unclear; however, earlier onset appears associated with moderate-to-high levels of exposure to asbestos [<a href="#rid77">77</a>]. (See <a class="local">'Clinical findings'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Symptoms of BAPE are nonspecific and include pleuritic chest pain, dyspnea, chronic cough, and less commonly fever [<a href="#rid73">73,78</a>]. In asbestos-exposed workers being monitored by interval chest radiographs, BAPEs were asymptomatic in 66 percent [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – BAPEs are usually unilateral and may be associated with other evidence of asbestos-related pleural disease  (<a class="graphic graphic_diagnosticimage graphicRef91547" href="/z/d/graphic/91547.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef91467" href="/z/d/graphic/91467.html" rel="external">image 6</a>). In a series of 36 patients with BAPE, CT imaging identified concomitant pleural plaques in 92 percent, rounded atelectasis in 44 percent, pleural calcification in 25 percent, and diffuse pleural thickening in 25 percent [<a href="#rid76">76</a>]. </p><p></p><p class="bulletIndent1">Pleural adhesions due to the inflammatory process of BAPE can cause atelectasis of a part of the peripheral lung, and this often takes on a rounded appearance on chest radiograph (ie, "rounded atelectasis")  (<a class="graphic graphic_diagnosticimage graphicRef82006 graphicRef78745" href="/z/d/graphic/82006.html" rel="external">image 7A-B</a>). Rounded atelectasis can occur as a result of any type of pleural inflammation, but is most often associated with asbestos exposure  (<a class="graphic graphic_picture graphicRef68171" href="/z/d/graphic/68171.html" rel="external">picture 5</a>) [<a href="#rid76">76,79-81</a>]. (See  <a class="medical medical_review" href="/z/d/html/14874.html" rel="external">"Imaging of occupational lung diseases", section on 'Pleural disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid</strong> – The pleural fluid is exudative and can be serous, serosanguinous, or overtly bloody. Approximately one-third of BAPEs have increased pleural eosinophils, sometimes up to 50 percent of the total nucleated cell count [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – BAPE may be suspected on the basis of a compatible history and timing of asbestos exposure, but the diagnosis of BAPE is based on exclusion of other causes of exudative effusion (eg, infection, rheumatoid pleuritis, and malignancy) and spontaneous resolution of the effusion. The likelihood of BAPE is increased by the presence of pleural plaques with linear calcification [<a href="#rid76">76</a>]. However, exclusion of pleural malignancy may require closed pleural biopsy or thoracoscopic evaluation. (See  <a class="medical medical_review" href="/z/d/html/6698.html" rel="external">"Pleural fluid analysis in adults with a pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6707.html" rel="external">"Diagnostic evaluation of the hemodynamically stable adult with a pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6699.html" rel="external">"Medical thoracoscopy (pleuroscopy): Diagnostic and therapeutic applications"</a>.)</p><p></p><p class="bulletIndent1">As lung cancer and mesothelioma occur with increased frequency among asbestos-exposed workers, pleural effusions due to mesothelioma or spread of lung cancer are prominent in the differential diagnosis. When reviewing the CT scan in a patient with suspected BAPE, the presence of mediastinal pleural plaques increases the likelihood of mesothelioma, as mediastinal plaques were noted in 22 percent of patients with BAPE compared with 74 percent of patients with mesothelioma [<a href="#rid76">76</a>]. Irregularity or nodularity of the interlobular septa is substantially more common in mesothelioma than BAPE [<a href="#rid76">76</a>], as are chest wall and rib involvement. (See <a class="local">'Malignant mesothelioma'</a> below and  <a class="medical medical_review" href="/z/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors", section on 'Malignant mesothelioma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course</strong> – BAPEs typically resolve spontaneously over the course of several weeks to months (mean 4.3 months [<a href="#rid75">75</a>]), but can persist for up to a year. BAPEs can recur on the same or opposite side in approximately 30 percent of affected individuals [<a href="#rid73">73,75</a>]. As the pleural fluid of BAPE regresses, it may leave visible blunting of the costophrenic angle and/or diffuse pleural thickening of the visceral pleura. BAPEs do not predict an increased risk of mesothelioma beyond that of individuals with similar asbestos exposure without BAPE. (See <a class="local">'Pleural plaques and diffuse pleural thickening'</a> below.)</p><p></p><p class="headingAnchor" id="H1203525457"><span class="h2">Pleural plaques and diffuse pleural thickening</span><span class="headingEndMark"> — </span>Pleural plaques and diffuse pleural thickening are benign consequences of asbestos exposure. </p><p>Pleural plaques are circumscribed areas of pleural thickening with a linear, band-like, or nodular appearance. They are composed of deposits of collagen in the parietal pleura. Approximately 60 percent of persons with work-related asbestos exposure manifest pleural plaques when screened by low dose CT [<a href="#rid83">83</a>]. </p><p>The plaques preferentially involve the parietal pleura adjacent to ribs, are less extensive in the intercostal spaces, and only rarely occur on the visceral pleura. Plaques are most commonly found along the sixth through ninth ribs and along the diaphragm and are typically bilateral  (<a class="graphic graphic_diagnosticimage graphicRef52721" href="/z/d/graphic/52721.html" rel="external">image 8</a> and <a class="graphic graphic_diagnosticimage graphicRef91626" href="/z/d/graphic/91626.html" rel="external">image 9</a> and <a class="graphic graphic_diagnosticimage graphicRef91464" href="/z/d/graphic/91464.html" rel="external">image 10</a> and <a class="graphic graphic_picture graphicRef73648" href="/z/d/graphic/73648.html" rel="external">picture 3</a>). They are conspicuously absent in the region of the costophrenic sulci and at the lung apices. Calcifications are identified by chest radiography in 20 percent, on CT scanning in 50 percent, and at morphologic examination in 80 percent. (See  <a class="medical medical_review" href="/z/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors"</a>.)</p><p>Diffuse pleural thickening is defined based on the CT appearance: the pleural thickness is &gt;3 mm, extends craniocaudad &gt;8 cm, and extends axially &gt;5 cm. It typically obliterates the costophrenic sulci. (See  <a class="medical medical_review" href="/z/d/html/4399.html" rel="external">"Imaging of pleural plaques, thickening, and tumors", section on 'Diffuse pleural thickening'</a>.)</p><p>One area of controversy has been whether circumscribed pleural plaques can contribute to respiratory impairment and a restrictive pattern on lung function testing (reduced forced vital capacity [FVC]) in the absence of asbestosis [<a href="#rid1">1</a>]. This has been difficult to ascertain due to confounders such as age, lung parenchymal disease, and cigarette smoking. In one study, pleural plaques were associated with a small decrement in FVC (140 mL, p = 0.02), but less than that associated with diffuse pleural thickening (270 mL, p = 0.005) [<a href="#rid84">84</a>]. </p><p>Rounded atelectasis may develop in patients with pleural plaques without known presence of BAPE. As with BAPE, pleural inflammation is thought to cause adherence of the pleura to a portion of peripheral lung, causing a small, rounded area of collapsed lung  (<a class="graphic graphic_diagnosticimage graphicRef82006 graphicRef78745" href="/z/d/graphic/82006.html" rel="external">image 7A-B</a>). Rounded atelectasis can occur as a result of any type of pleural inflammation, but is most often associated with asbestos exposure  (<a class="graphic graphic_picture graphicRef68171" href="/z/d/graphic/68171.html" rel="external">picture 5</a>) [<a href="#rid79">79-81</a>]. (See <a class="local">'Benign asbestos pleural effusion'</a> above.)</p><p class="headingAnchor" id="H177468456"><span class="h2">Malignant mesothelioma</span><span class="headingEndMark"> — </span>Malignant mesothelioma, which is highly associated with asbestos exposure, is a rare neoplasm that arises from mesothelial surface of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium [<a href="#rid85">85,86</a>]. Malignant pleural mesothelioma (MPM) is the most common type. In one study of 66 patients with MPM, the mean duration of asbestos exposure was 17 years and a mean latency from exposure to disease presentation of 24 years [<a href="#rid76">76</a>]. Symptoms are nonspecific and include chest pain, dyspnea, cough, and night sweats. Invasion of local structures can cause additional symptoms. (See  <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H4177357801"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118850.html" rel="external">"Society guideline links: Pneumoconiosis"</a>.)</p><p class="headingAnchor" id="H107818520"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83057.html" rel="external">"Patient education: Asbestos exposure (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Asbestosis specifically refers to the pneumoconiosis caused by inhalation of asbestos fibers. The disease is characterized by slowly progressive, diffuse pulmonary fibrosis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to asbestos occurs during the mining and milling of the fibers, in industrial applications of asbestos (eg, work with cement, friction materials, insulation, shipbuilding), and in nonoccupational settings with airborne asbestos (eg, regular exposure to soiled work clothes brought home by an asbestos worker, renovation or demolition of asbestos-containing buildings). (See <a class="local">'Asbestos exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients who develop asbestosis are asymptomatic for at least 20 to 30 years after the initial exposure; the latency period between exposure and symptoms is inversely proportional to the intensity of asbestos exposure. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The earliest symptom of asbestosis is usually the insidious onset of breathlessness with exertion, which progresses even in the absence of further asbestos exposure. Cough, sputum production, and wheezing are unusual. (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typical high resolution computed tomography (HRCT) scan findings of asbestosis include: subpleural linear densities of varying length parallel to the pleura, basilar and dorsal lung parenchymal fibrosis, with peribronchiolar, intralobular, and interlobular septal fibrosis, coarse parenchymal bands (2 to 5 cm in length), often contiguous with the pleura, coarse honeycombing in advanced disease, and pleural plaques  (<a class="graphic graphic_diagnosticimage graphicRef91464" href="/z/d/graphic/91464.html" rel="external">image 10</a> and <a class="graphic graphic_diagnosticimage graphicRef91626" href="/z/d/graphic/91626.html" rel="external">image 9</a>). (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of asbestosis is based on a reliable history of exposure to asbestos with a proper latency period, and/or presence of markers of exposure (eg, pleural plaques or recovery of sufficient quantities of asbestos fibers/bodies in bronchoalveolar lavage or lung tissue); definite evidence of interstitial fibrosis (eg, end-inspiratory crackles, reduced lung volumes and/or diffusing capacity, typical radiographic findings, or histologic evidence of interstitial fibrosis); and absence of other causes of diffuse parenchymal lung disease. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No specific treatment has been identified for asbestosis. Management includes supportive care with an emphasis on smoking cessation, avoidance of further asbestos exposure, pneumococcal and influenza vaccination, and supplemental oxygen as needed to maintain adequate oxygenation. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benign asbestos pleural effusions (BAPEs) are usually small and unilateral and occur years before the onset of interstitial disease. Typically, BAPEs resolve spontaneously over several months, but may recur. (See <a class="local">'Benign asbestos pleural effusion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pleural plaques and diffuse pleural thickening are benign consequences of asbestos exposure. Pleural plaques are circumscribed areas of pleural thickening with a linear, band-like, or nodular appearance, which may have areas of calcification. Diffuse pleural thickening, which may follow BAPE, is characterized by a pleural thickness &gt;3 mm, extension craniocaudad &gt;8 cm, and extension axially &gt;5 cm. (See <a class="local">'Pleural plaques and diffuse pleural thickening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant mesothelioma, which is highly associated with asbestos exposure, is a rare neoplasm that arises from mesothelial surface of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. (See <a class="local">'Malignant mesothelioma'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Steele M, Schwarz DA. Asbestosis and asbestos-induced pleural disease. In: Interstitial lung disease, 5th, Schwarz MI, King TE, Jr (Eds), People's Medical Publishing House, Shelton, CT 2011. p.543.</li><li><a class="nounderline abstract_t">Baur X, Woitowitz HJ, Budnik LT, et al. Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update. Am J Ind Med 2017; 60:411.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Asbestosis-related years of potential life lost before age 65 years--United States, 1968-2005. MMWR Morb Mortal Wkly Rep 2008; 57:1321.</a></li><li><a class="nounderline abstract_t">Yang M, Wang D, Gan S, et al. Increasing incidence of asbestosis worldwide, 1990-2017: results from the Global Burden of Disease study 2017. Thorax 2020; 75:798.</a></li><li><a class="nounderline abstract_t">Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989; 320:1721.</a></li><li><a class="nounderline abstract_t">Mossman BT, Bignon J, Corn M, et al. Asbestos: scientific developments and implications for public policy. Science 1990; 247:294.</a></li><li><a class="nounderline abstract_t">Wagner GR. Asbestosis and silicosis. Lancet 1997; 349:1311.</a></li><li><a class="nounderline abstract_t">Sichletidis L, Chloros D, Spyratos D, et al. Mortality from occupational exposure to relatively pure chrysotile: a 39-year study. Respiration 2009; 78:63.</a></li><li class="breakAll">World Health Organization. Chrysotile Asbestos. 2014. http://www.who.int/ipcs/assessment/public_health/chrysotile_asbestos_summary.pdf (Accessed on October 31, 2016).</li><li><a class="nounderline abstract_t">Thomsen RW, Riis AH, Flachs EM, et al. Risk of asbestosis, mesothelioma, other lung disease or death among motor vehicle mechanics: a 45-year Danish cohort study. Thorax 2022; 77:477.</a></li><li class="breakAll">Ogunseitan OA. The asbestos paradox: global gaps in the translational science of disease prevention. Bulletin of the World Health Organization. http://www.who.int/bulletin/volumes/93/5/14-142307/en/ (Accessed on October 18, 2016).</li><li><a class="nounderline abstract_t">Reid A, Berry G, de Klerk N, et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest 2007; 131:376.</a></li><li><a class="nounderline abstract_t">Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172:1019.</a></li><li><a class="nounderline abstract_t">Kurumatani N, Kumagai S. Mapping the risk of mesothelioma due to neighborhood asbestos exposure. Am J Respir Crit Care Med 2008; 178:624.</a></li><li><a class="nounderline abstract_t">Hansell A. Airborne environmental exposure to asbestos. Am J Respir Crit Care Med 2008; 178:556.</a></li><li><a class="nounderline abstract_t">Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157:1666.</a></li><li><a class="nounderline abstract_t">Craighead JE, Abraham JL, Churg A, et al. The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health. Arch Pathol Lab Med 1982; 106:544.</a></li><li><a class="nounderline abstract_t">Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society. Arch Pathol Lab Med 2010; 134:462.</a></li><li><a class="nounderline abstract_t">Roggli VL. Human disease consequences of fiber exposures: a review of human lung pathology and fiber burden data. Environ Health Perspect 1990; 88:295.</a></li><li><a class="nounderline abstract_t">Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am Rev Respir Dis 1991; 143:408.</a></li><li><a class="nounderline abstract_t">Brody AR. Asbestos-induced lung disease. Environ Health Perspect 1993; 100:21.</a></li><li><a class="nounderline abstract_t">Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax 1999; 54:638.</a></li><li><a class="nounderline abstract_t">Brody AR, Hill LH, Adkins B Jr, O'Connor RW. Chrysotile asbestos inhalation in rats: deposition pattern and reaction of alveolar epithelium and pulmonary macrophages. Am Rev Respir Dis 1981; 123:670.</a></li><li><a class="nounderline abstract_t">Pinkerton KE, Pratt PC, Brody AR, Crapo JD. Fiber localization and its relationship to lung reaction in rats after chronic inhalation of chrysotile asbestos. Am J Pathol 1984; 117:484.</a></li><li><a class="nounderline abstract_t">Chang LY, Overby LH, Brody AR, Crapo JD. Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol 1988; 131:156.</a></li><li><a class="nounderline abstract_t">Churg A, Stevens B. Enhanced retention of asbestos fibers in the airways of human smokers. Am J Respir Crit Care Med 1995; 151:1409.</a></li><li><a class="nounderline abstract_t">Blanc PD, Golden JA, Gamsu G, et al. Asbestos exposure-cigarette smoking interactions among shipyard workers. JAMA 1988; 259:370.</a></li><li><a class="nounderline abstract_t">Hourihane DO, McCaughey WT. Pathological aspects of asbestosis. Postgrad Med J 1966; 42:613.</a></li><li><a class="nounderline abstract_t">Lemaire I. Characterization of the bronchoalveolar cellular response in experimental asbestosis. Different reactions depending on the fibrogenic potential. Am Rev Respir Dis 1985; 131:144.</a></li><li><a class="nounderline abstract_t">Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest 1991; 100:248.</a></li><li class="breakAll">Fraser RG, Pare JAP, Pare PD, et al. Pleuropulmonary disease caused by inhalation of inorganic dust (pneumoconiosis). In: Diagnosis of Diseases of the Chest, Fraser RG, Fraser RS Genereux GP (Eds), 1990. p.2346.</li><li><a class="nounderline abstract_t">Murphy RL Jr, Gaensler EA, Holford SK, et al. Crackles in the early detection of asbestosis. Am Rev Respir Dis 1984; 129:375.</a></li><li><a class="nounderline abstract_t">Turner-Warwick M, Parkes WR. Circulating rheumatoid and antinuclear factors in asbestos workers. Br Med J 1970; 3:492.</a></li><li><a class="nounderline abstract_t">American Thoracic Society. Medical Section of the American Lung Association: The diagnosis of nonmalignant diseases related to asbestos. Am Rev Respir Dis 1986; 134:363.</a></li><li><a class="nounderline abstract_t">Kilburn KH, Warshaw RH. Airways obstruction from asbestos exposure. Effects of asbestosis and smoking. Chest 1994; 106:1061.</a></li><li><a class="nounderline abstract_t">Freundlich, IM, Greening, RR. Asbestos and associated medical problems. Radiology 1967; 89:224.</a></li><li><a class="nounderline abstract_t">Larson TC, Meyer CA, Kapil V, et al. Workers with Libby amphibole exposure: retrospective identification and progression of radiographic changes. Radiology 2010; 255:924.</a></li><li><a class="nounderline abstract_t">Kipen HM, Lilis R, Suzuki Y, et al. Pulmonary fibrosis in asbestos insulation workers with lung cancer: a radiological and histopathological evaluation. Br J Ind Med 1987; 44:96.</a></li><li><a class="nounderline abstract_t">Sette A, Neder JA, Nery LE, et al. Thin-section CT abnormalities and pulmonary gas exchange impairment in workers exposed to asbestos. Radiology 2004; 232:66.</a></li><li><a class="nounderline abstract_t">Aberle DR, Gamsu G, Ray CS. High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation. AJR Am J Roentgenol 1988; 151:883.</a></li><li><a class="nounderline abstract_t">Staples CA, Gamsu G, Ray CS, Webb WR. High resolution computed tomography and lung function in asbestos-exposed workers with normal chest radiographs. Am Rev Respir Dis 1989; 139:1502.</a></li><li><a class="nounderline abstract_t">Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 1990; 142:1206.</a></li><li><a class="nounderline abstract_t">Banks DE, Shi R, McLarty J, et al. American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest 2009; 135:1619.</a></li><li><a class="nounderline abstract_t">Gamsu G, Salmon CJ, Warnock ML, Blanc PD. CT quantification of interstitial fibrosis in patients with asbestosis: a comparison of two methods. AJR Am J Roentgenol 1995; 164:63.</a></li><li><a class="nounderline abstract_t">Aberle DR, Gamsu G, Ray CS, Feuerstein IM. Asbestos-related pleural and parenchymal fibrosis: detection with high-resolution CT. Radiology 1988; 166:729.</a></li><li><a class="nounderline abstract_t">Aberle DR, Balmes JR. Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases. Clin Chest Med 1991; 12:115.</a></li><li><a class="nounderline abstract_t">Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 2. Am Rev Respir Dis 1990; 142:1440.</a></li><li><a class="nounderline abstract_t">Teschler H, Thompson AB, Dollenkamp R, et al. Relevance of asbestos bodies in sputum. Eur Respir J 1996; 9:680.</a></li><li><a class="nounderline abstract_t">De Vuyst P, Jedwab J, Dumortier P, et al. Asbestos bodies in bronchoalveolar lavage. Am Rev Respir Dis 1982; 126:972.</a></li><li><a class="nounderline abstract_t">Sebastien P, Armstrong B, Monchaux G, Bignon J. Asbestos bodies in bronchoalveolar lavage fluid and in lung parenchyma. Am Rev Respir Dis 1988; 137:75.</a></li><li><a class="nounderline abstract_t">Karjalainen A, Piipari R, Mäntylä T, et al. Asbestos bodies in bronchoalveolar lavage in relation to asbestos bodies and asbestos fibres in lung parenchyma. Eur Respir J 1996; 9:1000.</a></li><li><a class="nounderline abstract_t">A physician's guide to asbestos-related diseases. Council on Scientific Affairs. JAMA 1984; 252:2593.</a></li><li><a class="nounderline abstract_t">Mizell KN, Morris CG, Carter JE. Antemortem diagnosis of asbestosis by screening chest radiograph correlated with postmortem histologic features of asbestosis: a study of 273 cases. J Occup Med Toxicol 2009; 4:14.</a></li><li><a class="nounderline abstract_t">Miedema JR, Moor CC, Veltkamp M, et al. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respir Res 2022; 23:139.</a></li><li><a class="nounderline abstract_t">Wilt JL, Banks DE, Weissman DN, et al. Reduction of lung dust burden in pneumoconiosis by whole-lung lavage. J Occup Environ Med 1996; 38:619.</a></li><li><a class="nounderline abstract_t">Schwartz DA, Davis CS, Merchant JA, et al. Longitudinal changes in lung function among asbestos-exposed workers. Am J Respir Crit Care Med 1994; 150:1243.</a></li><li><a class="nounderline abstract_t">Millaire É, Lévesque M, Lemière C, et al. Progression of Pulmonary Fibrosis According to Radiological Pattern in Asbestosis. Ann Am Thorac Soc 2023; 20:328.</a></li><li><a class="nounderline abstract_t">Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684.</a></li><li><a class="nounderline abstract_t">Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167:962.</a></li><li><a class="nounderline abstract_t">Keskitalo E, Salonen J, Vähänikkilä H, Kaarteenaho R. Survival of patients with asbestosis can be assessed by risk-predicting models. Occup Environ Med 2021; 78:516.</a></li><li><a class="nounderline abstract_t">Tron V, Wright JL, Harrison N, et al. Cigarette smoke makes airway and early parenchymal asbestos-induced lung disease worse in the guinea pig. Am Rev Respir Dis 1987; 136:271.</a></li><li><a class="nounderline abstract_t">Kamp DW, Graceffa P, Pryor WA, Weitzman SA. The role of free radicals in asbestos-induced diseases. Free Radic Biol Med 1992; 12:293.</a></li><li><a class="nounderline abstract_t">Warnock ML, Isenberg W. Asbestos burden and the pathology of lung cancer. Chest 1986; 89:20.</a></li><li><a class="nounderline abstract_t">Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. Am J Respir Crit Care Med 2013; 188:90.</a></li><li><a class="nounderline abstract_t">Azzolina D, Consonni D, Ferrante D, et al. Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers. Thorax 2023; 78:808.</a></li><li><a class="nounderline abstract_t">van Loon AJ, Kant IJ, Swaen GM, et al. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occup Environ Med 1997; 54:817.</a></li><li><a class="nounderline abstract_t">Kwak K, Kang D, Paek D. Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis. Occup Environ Med 2022; 79:207.</a></li><li><a class="nounderline abstract_t">Ngamwong Y, Tangamornsuksan W, Lohitnavy O, et al. Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLoS One 2015; 10:e0135798.</a></li><li><a class="nounderline abstract_t">Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 1979; 330:473.</a></li><li class="breakAll">Hughes, JM, Weill, H. Asbestos and man-made fibers. In: Samet, JM, (Ed), Epidemiology of Lung Cancer, Marcel Dekker, New York, 1994, p. 185.</li><li><a class="nounderline abstract_t">Deng Q, Wang X, Wang M, Lan Y. Exposure-response relationship between chrysotile exposure and mortality from lung cancer and asbestosis. Occup Environ Med 2012; 69:81.</a></li><li><a class="nounderline abstract_t">Selikoff IJ. Historical developments and perspectives in inorganic fiber toxicity in man. Environ Health Perspect 1990; 88:269.</a></li><li><a class="nounderline abstract_t">Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 1982; 247:617.</a></li><li><a class="nounderline abstract_t">Paris C, Thierry S, Brochard P, et al. Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J 2009; 34:72.</a></li><li><a class="nounderline abstract_t">Robinson BW, Musk AW. Benign asbestos pleural effusion: diagnosis and course. Thorax 1981; 36:896.</a></li><li><a class="nounderline abstract_t">Kato K, Gemba K, Fujimoto N, et al. Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion. Eur J Radiol 2016; 85:1594.</a></li><li><a class="nounderline abstract_t">Fujimoto N, Gemba K, Aoe K, et al. Clinical Investigation of Benign Asbestos Pleural Effusion. Pulm Med 2015; 2015:416179.</a></li><li><a class="nounderline abstract_t">Hillerdal G, Ozesmi M. Benign asbestos pleural effusion: 73 exudates in 60 patients. Eur J Respir Dis 1987; 71:113.</a></li><li><a class="nounderline abstract_t">Mintzer RA, Cugell DW. The association of asbestos-induced pleural disease and rounded atelectasis. Chest 1982; 81:457.</a></li><li><a class="nounderline abstract_t">Hillerdal G. Rounded atelectasis. Clinical experience with 74 patients. Chest 1989; 95:836.</a></li><li><a class="nounderline abstract_t">Voisin C, Fisekci F, Voisin-Saltiel S, et al. Asbestos-related rounded atelectasis. Radiologic and mineralogic data in 23 cases. Chest 1995; 107:477.</a></li><li><a class="nounderline abstract_t">Mattson SB. Monosymptomatic exudative pleurisy in persons exposed to asbestos dust. Scand J Respir Dis 1975; 56:263.</a></li><li><a class="nounderline abstract_t">Murray CP, Wong PM, Teh J, et al. Ultra low dose CT screen-detected non-malignant incidental findings in the Western Australian Asbestos Review Programme. Respirology 2016; 21:1419.</a></li><li><a class="nounderline abstract_t">Schwartz DA, Fuortes LJ, Galvin JR, et al. Asbestos-induced pleural fibrosis and impaired lung function. Am Rev Respir Dis 1990; 141:321.</a></li><li><a class="nounderline abstract_t">Kradin RL, Eng G, Christiani DC. Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos. Am J Ind Med 2017; 60:963.</a></li><li><a class="nounderline abstract_t">Marsh GM, Riordan AS, Keeton KA, Benson SM. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med 2017; 74:838.</a></li></ol></div><div id="topicVersionRevision">Topic 4307 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Steele M, Schwarz DA. Asbestosis and asbestos-induced pleural disease. In: Interstitial lung disease, 5th, Schwarz MI, King TE, Jr (Eds), People's Medical Publishing House, Shelton, CT 2011. p.543.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28409857" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19078920" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Asbestosis-related years of potential life lost before age 65 years--United States, 1968-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32467338" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Increasing incidence of asbestosis worldwide, 1990-2017: results from the Global Burden of Disease study 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2659987" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Asbestos-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2153315" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Asbestos: scientific developments and implications for public policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142077" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Asbestosis and silicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843176" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mortality from occupational exposure to relatively pure chrysotile: a 39-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843176" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mortality from occupational exposure to relatively pure chrysotile: a 39-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34244457" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of asbestosis, mesothelioma, other lung disease or death among motor vehicle mechanics: a 45-year Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34244457" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of asbestosis, mesothelioma, other lung disease or death among motor vehicle mechanics: a 45-year Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296636" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976368" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Residential proximity to naturally occurring asbestos and mesothelioma risk in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556631" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mapping the risk of mesothelioma due to neighborhood asbestos exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18755931" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Airborne environmental exposure to asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603153" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mechanisms in the pathogenesis of asbestosis and silicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897166" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20196674" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2272326" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Human disease consequences of fiber exposures: a review of human lung pathology and fiber burden data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1990961" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cellular and molecular basis of the asbestos-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354168" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Asbestos-induced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10377212" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The molecular basis of asbestos induced lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6267971" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chrysotile asbestos inhalation in rats: deposition pattern and reaction of alveolar epithelium and pulmonary macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6095671" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fiber localization and its relationship to lung reaction in rats after chronic inhalation of chrysotile asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2833103" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7735593" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Enhanced retention of asbestos fibers in the airways of human smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336160" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Asbestos exposure-cigarette smoking interactions among shipyard workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5331865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pathological aspects of asbestosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966702" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characterization of the bronchoalveolar cellular response in experimental asbestosis. Different reactions depending on the fibrogenic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2060355" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2060355" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6367573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Crackles in the early detection of asbestosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4918296" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Circulating rheumatoid and antinuclear factors in asbestos workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740660" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : American Thoracic Society. Medical Section of the American Lung Association: The diagnosis of nonmalignant diseases related to asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924474" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Airways obstruction from asbestos exposure. Effects of asbestosis and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Asbestos and associated medical problems</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501730" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Workers with Libby amphibole exposure: retrospective identification and progression of radiographic changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3814551" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulmonary fibrosis in asbestos insulation workers with lung cancer: a radiological and histopathological evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220494" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thin-section CT abnormalities and pulmonary gas exchange impairment in workers exposed to asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263018" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729755" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High resolution computed tomography and lung function in asbestos-exposed workers with normal chest radiographs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240845" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Computed tomography of chronic diffuse infiltrative lung disease. Part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19497896" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7998570" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CT quantification of interstitial fibrosis in patients with asbestosis: a comparison of two methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3340770" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Asbestos-related pleural and parenchymal fibrosis: detection with high-resolution CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009740" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2252265" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Computed tomography of chronic diffuse infiltrative lung disease. Part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8726931" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Relevance of asbestos bodies in sputum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7181238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Asbestos bodies in bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337472" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Asbestos bodies in bronchoalveolar lavage fluid and in lung parenchyma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793463" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Asbestos bodies in bronchoalveolar lavage in relation to asbestos bodies and asbestos fibres in lung parenchyma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6492343" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A physician's guide to asbestos-related diseases. Council on Scientific Affairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19523203" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antemortem diagnosis of asbestosis by screening chest radiograph correlated with postmortem histologic features of asbestosis: a study of 273 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643466" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794962" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reduction of lung dust burden in pneumoconiosis by whole-lung lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952547" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Longitudinal changes in lung function among asbestos-exposed workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36322448" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Progression of Pulmonary Fibrosis According to Radiological Pattern in Asbestosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586007" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A multidimensional index and staging system for idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663338" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637623" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Survival of patients with asbestosis can be assessed by risk-predicting models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2887135" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cigarette smoke makes airway and early parenchymal asbestos-induced lung disease worse in the guinea pig.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1577332" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The role of free radicals in asbestos-induced diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940784" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Asbestos burden and the pathology of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590275" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36357176" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9538355" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33972375" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26274395" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/294198" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Asbestos exposure, cigarette smoking and death rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/294198" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Asbestos exposure, cigarette smoking and death rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742741" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Exposure-response relationship between chrysotile exposure and mortality from lung cancer and asbestosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2272322" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Historical developments and perspectives in inorganic fiber toxicity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7054563" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevalence and incidence of benign asbestos pleural effusion in a working population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129281" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7336367" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Benign asbestos pleural effusion: diagnosis and course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27501894" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26689234" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical Investigation of Benign Asbestos Pleural Effusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3622660" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Benign asbestos pleural effusion: 73 exudates in 60 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7067512" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The association of asbestos-induced pleural disease and rounded atelectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924612" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Rounded atelectasis. Clinical experience with 74 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842780" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Asbestos-related rounded atelectasis. Radiologic and mineralogic data in 23 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1209200" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Monosymptomatic exudative pleurisy in persons exposed to asbestos dust.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27312516" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ultra low dose CT screen-detected non-malignant incidental findings in the Western Australian Asbestos Review Programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301850" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Asbestos-induced pleural fibrosis and impaired lung function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940402" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935666" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
